Repurposing of Drugs Targeting YAP-TEAD Functions
AbstractDrug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds. View Full-Text
Share & Cite This Article
Elisi, G.M.; Santucci, M.; D’Arca, D.; Lauriola, A.; Marverti, G.; Losi, L.; Scalvini, L.; Bolognesi, M.L.; Mor, M.; Costi, M.P. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers 2018, 10, 329.
Elisi GM, Santucci M, D’Arca D, Lauriola A, Marverti G, Losi L, Scalvini L, Bolognesi ML, Mor M, Costi MP. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers. 2018; 10(9):329.Chicago/Turabian Style
Elisi, Gian M.; Santucci, Matteo; D’Arca, Domenico; Lauriola, Angela; Marverti, Gaetano; Losi, Lorena; Scalvini, Laura; Bolognesi, Maria L.; Mor, Marco; Costi, Maria P. 2018. "Repurposing of Drugs Targeting YAP-TEAD Functions." Cancers 10, no. 9: 329.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.